ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biopharmaceutical company that applies a patented technology platform to discover and develop antibody therapies and therapeutic vaccines targeting neurodegenerative diseases. The company focuses on Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS), with a biological thesis centered on selectively targeting misfolded, toxic protein conformations. ProMIS has generated no product revenue and reported an operating loss of $40.2 million for the year ended December 31, 2025, and an accumulated deficit of $130.4 million as of December 31, 2025. The company funds operations through equity and warrant offerings, raising gross proceeds of $21.6 million in July 2025 and $75.5 million in January 2026 via private placements and registered direct offerings. ProMIS intends to commercialize through out-licensing and collaborative partnerships, under which it would receive license fees, royalties, and manufacturing revenue if product candidates are successfully developed by partners.

Revenue model

No product revenue as of FY2025. Intended future revenue model consists of license fees, royalty payments on product sales, and manufacturing revenue from collaborative out-licensing arrangements with commercial partners. Operations are currently funded through equity issuances and warrant exercises.

Products and services

Antibody therapies and therapeutic vaccines targeting misfolded proteins in Alzheimer's disease, multiple system atrophy, and amyotrophic lateral sclerosis, developed using a proprietary technology platform combining protein biology and computational methods.

Customers and end markets

No commercial customers as of FY2025. Target end markets are patients and healthcare systems treating Alzheimer's disease, multiple system atrophy, and amyotrophic lateral sclerosis. Prospective partners are large and mid-sized pharmaceutical companies capable of funding clinical development and commercialization.

Value-chain role

Early-stage drug discovery and preclinical/clinical development. ProMIS acts as a technology platform and IP licensor, intending to outsource manufacturing and partner with commercial-stage pharmaceutical companies for later-stage development and distribution.

Geographic exposure

Incorporated in Canada; files with the U.S. SEC and lists on a U.S. exchange. Subject to regulatory frameworks in the U.S., Canada, EU, and U.K. based on disclosure in the FY2025 10-K filed March 25, 2026.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Nymox Pharmaceutical Corp Xenon Pharmaceuticals Inc